The Stop Tuberculosis Partnership
The stop Tuberculosis (TB) partnership is a network of international organizations, countries, governmental and nongovernmental organizations, public and private sector donors, and individuals dedicated to the elimination of tuberculosis as a publi...
| Main Author: | |
|---|---|
| Format: | Publication |
| Language: | English en_US |
| Published: |
Washington, DC: World Bank
2017
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/800431468148515795/The-stop-tuberculosis-partnership http://hdl.handle.net/10986/28058 |
| id |
okr-10986-28058 |
|---|---|
| recordtype |
oai_dc |
| spelling |
okr-10986-280582021-04-23T14:04:45Z The Stop Tuberculosis Partnership Independent Evaluation Group ACQUIRED IMMUNODEFICIENCY SYNDROME ACQUISITION AIDS VACCINE ANTI-TB DRUGS ANTIGENS ANTIRETROVIRAL TREATMENT ARV BACTERIOLOGY BOARD MEETING BOARD MEMBER BURDEN OF DISEASE CAUSES OF DEATH CHARTER CHEMOTHERAPY CLINICAL TRIALS COLLECTIVE COLLECTIVE ACTION COMMUNICABLE DISEASES COMPANY CONFIRMED SPUTUM SMEAR CONSOLIDATION CONTROL PROGRAMS CORPORATE CONSTITUENCY CORPORATION CORPORATIONS DEVELOPMENT GRANT FACILITY DGF DIAGNOSIS DIAGNOSTICS DISABILITY DISEASE DISEASE CONTROL DNA DRUG COMPANIES DRUG RESISTANCE ENDEMIC COUNTRIES EPIDEMIC EPIDEMIOLOGICAL ASPECTS EPIDEMIOLOGY HEALTH CARE HEALTH SERVICES HEALTH STATUS HEALTH STATUS OF POOR HIB HIV HIV/AIDS IAVI IMMUNODEFICIENCY INDIVIDUALS INFECTION INFECTION CONTROL INFECTIOUS PATIENTS INTERESTED PARTIES INTERNATIONAL AIDS VACCINE INITIATIVE ISONIAZID LEPROSY LIMITED LUNG DISEASE LUNGS MALARIA MANAGERS MEMBER STATES MORTALITY NON-GOVERNMENTAL ORGANIZATION NON-GOVERNMENTAL ORGANIZATIONS PARTNERSHIP PARTNERSHIP FRAMEWORK PATIENTS PEDIATRIC TUBERCULOSIS PERSONS PREVALENCE PROPRIETARY PUBLIC HEALTH PULMONARY TUBERCULOSIS RESISTANT TUBERCULOSIS SECOND-LINE DRUGS SHORT COURSE CHEMOTHERAPY SMEAR POSITIVE SOCIETY SPUTUM SMEAR SPUTUM SMEAR MICROSCOPY STAKEHOLDER STAKEHOLDERS SYMPTOMATIC PATIENTS SELF-REPORTING SYMPTOMS TB TB CONTROL TREATMENT TREATMENT REGIMEN TROPICAL DISEASES TUBERCULOSIS TUBERCULOSIS CONTROL TUBERCULOSIS CONTROL STRATEGY TUBERCULOSIS EPIDEMIOLOGY TUBERCULOSIS PREVENTION UNION VACCINE VACCINE DEVELOPMENT VACCINE RESEARCH VACCINES VISION The stop Tuberculosis (TB) partnership is a network of international organizations, countries, governmental and nongovernmental organizations, public and private sector donors, and individuals dedicated to the elimination of tuberculosis as a public health problem. The partnership is a loose coalition of partners working to elevate action on tuberculosis, one of the leading causes of death from infectious disease, on the global agenda. The stop TB partnership was formally established in 2001, as it became clear to the international community that the initial targets set for TB control in 1991.The specific objectives for which the partnership has been accountable have evolved somewhat since 2001, and have recently been stated most clearly in the global plan to stop TB, 2006-2015. Since the present Global Program Review (GPR) covers the period from the initiation of the program to the present, it has reviewed the achievements of the stop TB partnership against four objectives which have been synthesized from core partnership documents going back to 2001, namely: 1) to expand the Directly Observed Treatment Short-Course (DOTS) strategy so that all people have access to effective diagnosis and treatment; 2) to develop and scale-up effective responses to the emerging challenges of drug resistance and HIV-related TB; 3) to improve and expand tools available for TB diagnosis, treatment and prevention; and 4) to strengthen the overall global partnership to stop TB so that proven TB-control strategies are effectively applied. 2017-08-29T15:23:08Z 2017-08-29T15:23:08Z 2009-11-19 Publication http://documents.worldbank.org/curated/en/800431468148515795/The-stop-tuberculosis-partnership 978-1-60244-125-5 http://hdl.handle.net/10986/28058 English en_US Global Program Review;Vol. 4(1) CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo World Bank Washington, DC: World Bank Publications & Research :: Publication Publications & Research |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
ACQUIRED IMMUNODEFICIENCY SYNDROME ACQUISITION AIDS VACCINE ANTI-TB DRUGS ANTIGENS ANTIRETROVIRAL TREATMENT ARV BACTERIOLOGY BOARD MEETING BOARD MEMBER BURDEN OF DISEASE CAUSES OF DEATH CHARTER CHEMOTHERAPY CLINICAL TRIALS COLLECTIVE COLLECTIVE ACTION COMMUNICABLE DISEASES COMPANY CONFIRMED SPUTUM SMEAR CONSOLIDATION CONTROL PROGRAMS CORPORATE CONSTITUENCY CORPORATION CORPORATIONS DEVELOPMENT GRANT FACILITY DGF DIAGNOSIS DIAGNOSTICS DISABILITY DISEASE DISEASE CONTROL DNA DRUG COMPANIES DRUG RESISTANCE ENDEMIC COUNTRIES EPIDEMIC EPIDEMIOLOGICAL ASPECTS EPIDEMIOLOGY HEALTH CARE HEALTH SERVICES HEALTH STATUS HEALTH STATUS OF POOR HIB HIV HIV/AIDS IAVI IMMUNODEFICIENCY INDIVIDUALS INFECTION INFECTION CONTROL INFECTIOUS PATIENTS INTERESTED PARTIES INTERNATIONAL AIDS VACCINE INITIATIVE ISONIAZID LEPROSY LIMITED LUNG DISEASE LUNGS MALARIA MANAGERS MEMBER STATES MORTALITY NON-GOVERNMENTAL ORGANIZATION NON-GOVERNMENTAL ORGANIZATIONS PARTNERSHIP PARTNERSHIP FRAMEWORK PATIENTS PEDIATRIC TUBERCULOSIS PERSONS PREVALENCE PROPRIETARY PUBLIC HEALTH PULMONARY TUBERCULOSIS RESISTANT TUBERCULOSIS SECOND-LINE DRUGS SHORT COURSE CHEMOTHERAPY SMEAR POSITIVE SOCIETY SPUTUM SMEAR SPUTUM SMEAR MICROSCOPY STAKEHOLDER STAKEHOLDERS SYMPTOMATIC PATIENTS SELF-REPORTING SYMPTOMS TB TB CONTROL TREATMENT TREATMENT REGIMEN TROPICAL DISEASES TUBERCULOSIS TUBERCULOSIS CONTROL TUBERCULOSIS CONTROL STRATEGY TUBERCULOSIS EPIDEMIOLOGY TUBERCULOSIS PREVENTION UNION VACCINE VACCINE DEVELOPMENT VACCINE RESEARCH VACCINES VISION |
| spellingShingle |
ACQUIRED IMMUNODEFICIENCY SYNDROME ACQUISITION AIDS VACCINE ANTI-TB DRUGS ANTIGENS ANTIRETROVIRAL TREATMENT ARV BACTERIOLOGY BOARD MEETING BOARD MEMBER BURDEN OF DISEASE CAUSES OF DEATH CHARTER CHEMOTHERAPY CLINICAL TRIALS COLLECTIVE COLLECTIVE ACTION COMMUNICABLE DISEASES COMPANY CONFIRMED SPUTUM SMEAR CONSOLIDATION CONTROL PROGRAMS CORPORATE CONSTITUENCY CORPORATION CORPORATIONS DEVELOPMENT GRANT FACILITY DGF DIAGNOSIS DIAGNOSTICS DISABILITY DISEASE DISEASE CONTROL DNA DRUG COMPANIES DRUG RESISTANCE ENDEMIC COUNTRIES EPIDEMIC EPIDEMIOLOGICAL ASPECTS EPIDEMIOLOGY HEALTH CARE HEALTH SERVICES HEALTH STATUS HEALTH STATUS OF POOR HIB HIV HIV/AIDS IAVI IMMUNODEFICIENCY INDIVIDUALS INFECTION INFECTION CONTROL INFECTIOUS PATIENTS INTERESTED PARTIES INTERNATIONAL AIDS VACCINE INITIATIVE ISONIAZID LEPROSY LIMITED LUNG DISEASE LUNGS MALARIA MANAGERS MEMBER STATES MORTALITY NON-GOVERNMENTAL ORGANIZATION NON-GOVERNMENTAL ORGANIZATIONS PARTNERSHIP PARTNERSHIP FRAMEWORK PATIENTS PEDIATRIC TUBERCULOSIS PERSONS PREVALENCE PROPRIETARY PUBLIC HEALTH PULMONARY TUBERCULOSIS RESISTANT TUBERCULOSIS SECOND-LINE DRUGS SHORT COURSE CHEMOTHERAPY SMEAR POSITIVE SOCIETY SPUTUM SMEAR SPUTUM SMEAR MICROSCOPY STAKEHOLDER STAKEHOLDERS SYMPTOMATIC PATIENTS SELF-REPORTING SYMPTOMS TB TB CONTROL TREATMENT TREATMENT REGIMEN TROPICAL DISEASES TUBERCULOSIS TUBERCULOSIS CONTROL TUBERCULOSIS CONTROL STRATEGY TUBERCULOSIS EPIDEMIOLOGY TUBERCULOSIS PREVENTION UNION VACCINE VACCINE DEVELOPMENT VACCINE RESEARCH VACCINES VISION Independent Evaluation Group The Stop Tuberculosis Partnership |
| relation |
Global Program Review;Vol. 4(1) |
| description |
The stop Tuberculosis (TB) partnership
is a network of international organizations, countries,
governmental and nongovernmental organizations, public and
private sector donors, and individuals dedicated to the
elimination of tuberculosis as a public health problem. The
partnership is a loose coalition of partners working to
elevate action on tuberculosis, one of the leading causes of
death from infectious disease, on the global agenda. The
stop TB partnership was formally established in 2001, as it
became clear to the international community that the initial
targets set for TB control in 1991.The specific objectives
for which the partnership has been accountable have evolved
somewhat since 2001, and have recently been stated most
clearly in the global plan to stop TB, 2006-2015. Since the
present Global Program Review (GPR) covers the period from
the initiation of the program to the present, it has
reviewed the achievements of the stop TB partnership against
four objectives which have been synthesized from core
partnership documents going back to 2001, namely: 1) to
expand the Directly Observed Treatment Short-Course (DOTS)
strategy so that all people have access to effective
diagnosis and treatment; 2) to develop and scale-up
effective responses to the emerging challenges of drug
resistance and HIV-related TB; 3) to improve and expand
tools available for TB diagnosis, treatment and prevention;
and 4) to strengthen the overall global partnership to stop
TB so that proven TB-control strategies are effectively applied. |
| format |
Publication |
| author |
Independent Evaluation Group |
| author_facet |
Independent Evaluation Group |
| author_sort |
Independent Evaluation Group |
| title |
The Stop Tuberculosis Partnership |
| title_short |
The Stop Tuberculosis Partnership |
| title_full |
The Stop Tuberculosis Partnership |
| title_fullStr |
The Stop Tuberculosis Partnership |
| title_full_unstemmed |
The Stop Tuberculosis Partnership |
| title_sort |
stop tuberculosis partnership |
| publisher |
Washington, DC: World Bank |
| publishDate |
2017 |
| url |
http://documents.worldbank.org/curated/en/800431468148515795/The-stop-tuberculosis-partnership http://hdl.handle.net/10986/28058 |
| _version_ |
1764465656719212544 |